GILEAD SCIENCES, INC.

Biological Products, (No Diagnostic Substances)·FOSTER CITY, CA·FY end 12/31·CIK 882095

CEO Pay Ratio

119:1

Daniel P. O’Day

CEO Total Comp

$28.4M

Daniel P. O’Day

Median Employee

$238,979

Revenue

$29.4B

FY 2025

Net Income

$8.5B

FY 2025

Free Cash Flow

$9.5B

FY 2025

Net Margin

28.9%

Insider Net (180d)

-$5.8M

0 buys / 10 sales

CEO Pay Accountability

CEO comp as % of net income

0.33%

For every $1,000 of profit, $3.34 flows to the CEO.

CEO comp as % of buybacks

1.48%

CEO comp equals 14.8‰ of cash returned to shareholders via buybacks.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	$29.4B	$28.8B	$27.1B	$27.3B	$27.3B
Gross Profit	—	—	—	—	—	—
Operating Income	$10.0B	$1.7B	$7.6B	$7.3B	$9.9B
Net Income	$8.5B	$480.0M	$5.7B	$4.6B	$6.2B
Operating CF	$10.0B	$10.8B	$8.0B	$9.1B	$11.4B
Capex	$563.0M	$523.0M	$585.0M	$728.0M	$579.0M
Free Cash Flow	$9.5B	$10.3B	$7.4B	$8.3B	$10.8B
Buybacks	$1.9B	$1.1B	$1.0B	$1.4B	$546.0M
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	34.0%	5.8%	28.0%	26.9%	36.3%
Net Margin	28.9%	1.7%	20.9%	16.8%	22.8%
FCF Margin	32.1%	35.8%	27.4%	30.6%	39.6%
R&D / Revenue	—	—	—	—	—	—
Effective Tax	13.1%	30.6%	18.2%	21.5%	25.1%
Debt / Equity	2.07	2.67	2.11	2.27	2.46
Buybacks / FCF	20.3%	11.2%	13.5%	16.7%	5.1%

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
Daniel P. O’DayChairman and Chief Executive Officer	$1.8M	$15.2M	$4.5M	$4.8M	$2.1M	$28.4M
Dietmar BergerM.D., Ph.D. Chief Medical Officer	$969.2K	$7.0M	$1.0M	$4.6M	$350.3K	$13.9M
Johanna MercierChief Commercial and Corporate Affairs Officer	$1.2M	$4.6M	$1.3M	$2.2M	$103.0K	$9.3M
Andrew D. DickinsonChief Financial Officer	$1.1M	$4.3M	$1.3M	$2.0M	$71.0K	$8.8M